Lantus Solostar is a prefilled insulin pen containing insulin glargine, a long-acting basal insulin used to treat type 1 and type 2 diabetes [1]. It is designed for daily injection [1].
What kind of insulin is in Lantus Solostar?
Lantus Solostar contains insulin glargine, which is a human insulin analog [1]. It is classified as a long-acting basal insulin, meaning it provides a steady background level of insulin throughout the day and night [2].
How does insulin glargine work?
Insulin glargine is engineered to have a longer duration of action compared to natural human insulin [3]. It is absorbed slowly from the injection site, providing a relatively constant plasma insulin concentration over a 24-hour period [3]. This helps to control blood glucose levels by facilitating glucose uptake into cells and reducing glucose production by the liver [4].
When does the patent for Lantus Solostar expire?
Information regarding the specific patent expiry dates for Lantus Solostar can be found on DrugPatentWatch.com [5]. Patents for branded drugs like Lantus often have multiple layers, including composition of matter patents and formulation patents, which can have different expiry dates [5].
Who makes Lantus Solostar?
Lantus Solostar is manufactured by Sanofi [1].
What are the alternatives to Lantus Solostar?
Several other long-acting basal insulins are available, including insulin detemir (Levemir) and insulin degludec (Tresiba) [6]. Biosimilar versions of insulin glargine are also available, which are highly similar to the reference product in terms of safety, purity, and potency [7].
What are the potential side effects of Lantus Solostar?
The most common side effect associated with Lantus Solostar, and all insulins, is hypoglycemia (low blood sugar) [1]. Other potential side effects include allergic reactions, injection site reactions, and changes in lipid levels [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].